Splenic marginal zone lymphoma: A US population‐based survival analysis (1999‐2016)
Abstract
Background: Splenic marginal zone lymphoma (SMZL) is a rare tumor without a uniform treatment approach. The authors describe a large population‐based study evaluating survival outcomes of patients with SMZL according to the treatment received.Methods: From the Surveillance, Epidemiology, and End Results database, patients were selected who had SMZL diagnosed from 1999 to 2016. Observation, splenectomy, chemotherapy, and splenectomy with chemotherapy were the evaluated treatment strategies. Cox and Fine and Gray regression models were used to evaluate overall and SMZL‐specific survival, respectively.Results: In total, 1671 patients were selected for the analysis. Most patients were aged >60 years (71.3%), White (89.7%), and non‐Hispanic (91.7%). Transformation to diffuse large B‐cell lymphoma (DLBCL) occurred in 71 patients (4.2%), and the 10‐year transformation rate was 8.6% (95% CI, 6.6%‐10.9%). In multivariable analysis, shorter SMZL‐specific survival was associated with age ≥60 years (subdistribution hazard ratio [SHR], 1.85; 95% CI, 1.40‐2.45; P < .001), Hispanic ethnicity (SHR, 1.50; 95% CI, 1.06‐2.13; P = .023), DLBCL transformation (SHR, 2.10; 95% CI, 1.48‐2.97; P < .001), and the presence of B‐symptoms (SHR, 1.67; 95% CI, 1.23‐2.27; P < .001). Compared with splenectomy, observation (SHR, 0.92; 95% CI, 0.67‐1.28; P = .636), chemotherapy only (SHR, 1.28; 95% CI, 0.93‐1.76; P = .127), and splenectomy plus chemotherapy (SHR, 1.43; 95% CI, 0.96‐2.13; P = .089) showed no significant differences in SMZL‐specific survival. Predictors of shorter overall survival were age ≥60 years (hazard ratio, 2.98; 95% CI, 2.37‐3.76; P < .001) and the presence of B‐symptoms (hazard ratio, 1.33; 95% CI, 1.06‐1.67; P = .014).Conclusions: There were no significant differences in overall or SMZL‐specific survival by treatment strategy. Older age, Hispanic ethnicity, DLBCL transformation, and B‐symptoms were associated with a worse prognosis.Keywords
Funding Information
- National Institutes of Health (K12CA226330)
- National Cancer Institute (1R01CA233945)
This publication has 24 references indexed in Scilit:
- Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab eraLeukemia Research, 2016
- Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over TimeClinical Cancer Research, 2015
- Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphomaAnnals of Hematology, 2013
- Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With SplenectomyThe Oncologist, 2013
- Splenic marginal zone lymphoma: a population-based study on the 2001–2008 incidence and survival in the United StatesLeukemia & Lymphoma, 2012
- Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphomaBritish Journal of Haematology, 2012
- Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesBritish Journal of Haematology, 2012
- Survival of patients with marginal zone lymphomaCancer, 2012
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneCancer, 2006
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999